Equine Encephalitis - Pipeline Review, H1 2016

  • ID: 3734747
  • Drug Pipelines
  • 51 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Akshaya Bio Inc.
  • Altravax, Inc.
  • EpiVax, Inc.
  • MORE
Equine Encephalitis - Pipeline Review, H1 2016

Summary

‘Equine Encephalitis - Pipeline Review, H1 2016’, provides an overview of the Equine Encephalitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Equine Encephalitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Equine Encephalitis and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Equine Encephalitis
- The report reviews pipeline therapeutics for Equine Encephalitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Equine Encephalitis therapeutics and enlists all their major and minor projects
- The report assesses Equine Encephalitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Equine Encephalitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Equine Encephalitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Equine Encephalitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akshaya Bio Inc.
  • Altravax, Inc.
  • EpiVax, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Equine Encephalitis Overview

Therapeutics Development

Pipeline Products for Equine Encephalitis - Overview

Pipeline Products for Equine Encephalitis - Comparative Analysis

Equine Encephalitis - Therapeutics under Development by Companies

Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes

Equine Encephalitis - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Equine Encephalitis - Products under Development by Companies

Equine Encephalitis - Products under Investigation by Universities/Institutes

Equine Encephalitis - Companies Involved in Therapeutics Development

Akshaya Bio Inc.

Altravax, Inc.

EpiVax, Inc.

Integrated BioTherapeutics, Inc.

Karyopharm Therapeutics, Inc.

Profectus BioSciences, Inc.

Equine Encephalitis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

DEF-201 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

equine encephalitis vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

equine encephalitis vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

equine encephalitis vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

imatinib mesylate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for Venezuelan Equine Encephalitis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

nilotinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TSI-GSD-104 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Vaccine for Western Equine Encephalitis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Venezuelan equine encephalitis vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Venezuelan equine encephalitis vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

verdinexor - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Westrern Equine Encephalitis Virus Vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Equine Encephalitis - Recent Pipeline Updates

Equine Encephalitis - Dormant Projects

Equine Encephalitis - Product Development Milestones

Featured News & Press Releases

Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses

Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Equine Encephalitis, H1 2016

Number of Products under Development for Equine Encephalitis - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Equine Encephalitis - Pipeline by Akshaya Bio Inc., H1 2016

Equine Encephalitis - Pipeline by Altravax, Inc., H1 2016

Equine Encephalitis - Pipeline by EpiVax, Inc., H1 2016

Equine Encephalitis - Pipeline by Integrated BioTherapeutics, Inc., H1 2016

Equine Encephalitis - Pipeline by Karyopharm Therapeutics, Inc., H1 2016

Equine Encephalitis - Pipeline by Profectus BioSciences, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Equine Encephalitis Therapeutics - Recent Pipeline Updates, H1 2016

Equine Encephalitis - Dormant Projects, H1 2016

List of Figures

Number of Products under Development for Equine Encephalitis, H1 2016

Number of Products under Development for Equine Encephalitis - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Akshaya Bio Inc.
Altravax, Inc.
EpiVax, Inc.
Integrated BioTherapeutics, Inc.
Karyopharm Therapeutics, Inc.
Profectus BioSciences, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll